Spinogenix, Inc.

Spinogenix is a clinical-stage biopharmaceutical company focused on developing novel therapies that restore synapses, the connections between neurons in the brain, to improve the lives of patients worldwide. Their lead drug candidates, SPG302 and SPG601, are first-in-class small molecule drugs designed to reverse the loss of synapses associated with neurodegenerative, neuropsychiatric, and neurodevelopmental conditions. Spinogenix's platform targets a wide range of diseases including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), schizophrenia, and Fragile X Syndrome.

Spinogenix's mission is to develop transformative treatments that can not only slow the progression of these debilitating diseases, but potentially reverse the decline in cognitive and motor function. They are actively conducting clinical trials for their drugs in Australia and the United States, and have secured several grants from the National Institutes of Health (NIH) and the Department of Defense (DoD) to support their research and development. With a focus on regenerative medicine, Spinogenix is aiming to change treatment paradigms and offer renewed hope for patients with a variety of neurological conditions.

Spinogenix is a clinical-stage biopharmaceutical company dedicated to developing first-in-class therapeutics that restore synapses to improve the lives of patients worldwide. Their mission is to provide transformative treatments for conditions involving the loss or dysfunction of synapses, which are the essential connections between neurons that allow us to think, plan, remember, and control motor functions. Spinogenix's unique approach aims to reverse declines in cognitive and motor function, potentially offering a fundamental shift in treatment paradigms for diseases like Alzheimer's, ALS, schizophrenia, and Fragile X Syndrome.

Spinogenix promotes a culture of innovation and collaboration, driven by a shared passion for developing transformative therapies to restore synaptic function and improve the lives of patients worldwide. The company emphasizes a patient-centric approach and fosters a collaborative environment where diverse perspectives are valued and encouraged. This culture is further reflected in the company's strong partnerships with leading academic institutions and research centers, as well as its commitment to transparent communication and continuous progress in clinical trials.